1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

: Invasion and Inflammation

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
  • Authors: Allister J. Loughran1, Carlos J. Orihuela2, Elaine I. Tuomanen3
  • Editors: Vincent A. Fischetti4, Richard P. Novick5, Joseph J. Ferretti6, Daniel A. Portnoy7, Miriam Braunstein8, Julian I. Rood9
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105; 2: Department of Microbiology, The University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294; 3: Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105; 4: The Rockefeller University, New York, NY; 5: Skirball Institute for Molecular Medicine, NYU Medical Center, New York, NY; 6: Department of Microbiology & Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK; 7: Department of Molecular and Cellular Microbiology, University of California, Berkeley, Berkeley, CA; 8: Department of Microbiology and Immunology, University of North Carolina-Chapel Hill, Chapel Hill, NC; 9: Infection and Immunity Program, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Australia
  • Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0004-2018
  • Received 30 April 2018 Accepted 19 October 2018 Published 15 March 2019
  • Elaine I. Tuomanen, [email protected]
image of <span class="jp-italic">Streptococcus pneumoniae</span>: Invasion and Inflammation
    Preview this microbiology spectrum article:
    Zoom in
    Zoomout

    : Invasion and Inflammation, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/7/2/GPP3-0004-2018-1.gif /docserver/preview/fulltext/microbiolspec/7/2/GPP3-0004-2018-2.gif
  • Abstract:

    Streptococcus pneumoniae (the pneumoccus) is the leading cause of otitis media, community-acquired pneumonia, and bacterial meningitis. The success of the pneumococcus stems from its ability to persist in the population as a commensal and avoid killing by immune system. This chapter first reviews the molecular mechanisms that allow the pneumococcus to colonize and spread from one anatomical site to the next. Then, it discusses the mechanisms of inflammation and cytotoxicity during emerging and classical pneumococcal infections.

  • Citation: Loughran A, Orihuela C, Tuomanen E. 2019. : Invasion and Inflammation. Microbiol Spectrum 7(2):GPP3-0004-2018. doi:10.1128/microbiolspec.GPP3-0004-2018.

References

1. Austrian R. 1986. Some aspects of the pneumococcal carrier state. J Antimicrob Chemother 18(Suppl A) :35–45. [PubMed]
2. Marks LR, Reddinger RM, Hakansson AP. 2014. Biofilm formation enhances fomite survival of Streptococcus pneumoniae and Streptococcus pyogenes. Infect Immun 82:1141–1146 http://dx.doi.org/10.1128/IAI.01310-13.[PubMed]
3. Musher DM. 2003. How contagious are common respiratory tract infections? N Engl J Med 348:1256–1266 http://dx.doi.org/10.1056/NEJMra021771. [PubMed]
4. Melegaro A, Gay NJ, Medley GF. 2004. Estimating the transmission parameters of pneumococcal carriage in households. Epidemiol Infect 132:433–441 http://dx.doi.org/10.1017/S0950268804001980. [PubMed]
5. Regev-Yochay G, Raz M, Dagan R, Porat N, Shainberg B, Pinco E, Keller N, Rubinstein E. 2004. Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clin Infect Dis 38:632–639 http://dx.doi.org/10.1086/381547. [PubMed]
6. Wyllie AL, Rümke LW, Arp K, Bosch AA, Bruin JP, Rots NY, Wijmenga-Monsuur AJ, Sanders EA, Trzciński K. 2016. Molecular surveillance on Streptococcus pneumoniae carriage in non-elderly adults; little evidence for pneumococcal circulation independent from the reservoir in children. Sci Rep 6:34888 http://dx.doi.org/10.1038/srep34888. [PubMed]
7. Wyllie AL, Wijmenga-Monsuur AJ, van Houten MA, Bosch AA, Groot JA, van Engelsdorp Gastelaars J, Bruin JP, Bogaert D, Rots NY, Sanders EA, Trzciński K. 2016. Molecular surveillance of nasopharyngeal carriage of Streptococcus pneumoniae in children vaccinated with conjugated polysaccharide pneumococcal vaccines. Sci Rep 6:23809 http://dx.doi.org/10.1038/srep23809. [PubMed]
8. Davidson M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters HV, Parks DJ. 1994. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990: ethnic differences and opportunities for prevention. J Infect Dis 170:368–376 http://dx.doi.org/10.1093/infdis/170.2.368. [PubMed]
9. Torzillo PJ, Hanna JN, Morey F, Gratten M, Dixon J, Erlich J. 1995. Invasive pneumococcal disease in central Australia. Med J Aust 162:182–186. [PubMed]
10. Morris PS, Leach AJ, Silberberg P, Mellon G, Wilson C, Hamilton E, Beissbarth J. 2005. Otitis media in young Aboriginal children from remote communities in Northern and Central Australia: a cross-sectional survey. BMC Pediatr 5:27 http://dx.doi.org/10.1186/1471-2431-5-27. [PubMed]
11. Mackenzie GA, Leach AJ, Carapetis JR, Fisher J, Morris PS. 2010. Epidemiology of nasopharyngeal carriage of respiratory bacterial pathogens in children and adults: cross-sectional surveys in a population with high rates of pneumococcal disease. BMC Infect Dis 10:304 http://dx.doi.org/10.1186/1471-2334-10-304. [PubMed]
12. Smith-Vaughan H, Marsh R, Mackenzie G, Fisher J, Morris PS, Hare K, McCallum G, Binks M, Murphy D, Lum G, Cook H, Krause V, Jacups S, Leach AJ. 2009. Age-specific cluster of cases of serotype 1 Streptococcus pneumoniae carriage in remote indigenous communities in Australia. Clin Vaccine Immunol 16:218–221 http://dx.doi.org/10.1128/CVI.00283-08. [PubMed]
13. Gray BM, Turner ME, Dillon HC Jr. 1982. Epidemiologic studies of Streptococcus pneumoniae in infants. The effects of season and age on pneumococcal acquisition and carriage in the first 24 months of life. Am J Epidemiol 116:692–703 http://dx.doi.org/10.1093/oxfordjournals.aje.a113452. [PubMed]
14. Gray BM, Converse GM III, Dillon HC Jr. 1980. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 142:923–933 http://dx.doi.org/10.1093/infdis/142.6.923. [PubMed]
15. Dunais B, Pradier C, Carsenti H, Sabah M, Mancini G, Fontas E, Dellamonica P. 2003. Influence of child care on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae. Pediatr Infect Dis J 22:589–592 http://dx.doi.org/10.1097/01.inf.0000073203.88387.eb. [PubMed]
16. Smith T, Lehmann D, Montgomery J, Gratten M, Riley ID, Alpers MP. 1993. Acquisition and invasiveness of different serotypes of Streptococcus pneumoniae in young children. Epidemiol Infect 111:27–39 http://dx.doi.org/10.1017/S0950268800056648. [PubMed]
17. Högberg L, Geli P, Ringberg H, Melander E, Lipsitch M, Ekdahl K. 2007. Age- and serogroup-related differences in observed durations of nasopharyngeal carriage of penicillin-resistant pneumococci. J Clin Microbiol 45:948–952 http://dx.doi.org/10.1128/JCM.01913-06. [PubMed]
18. Davis SM, Deloria-Knoll M, Kassa HT, O’Brien KL. 2013. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine 32:133–145 http://dx.doi.org/10.1016/j.vaccine.2013.05.005. [PubMed]
19. Nunes S, Sá-Leão R, Carriço J, Alves CR, Mato R, Avô AB, Saldanha J, Almeida JS, Sanches IS, de Lencastre H. 2005. Trends in drug resistance, serotypes, and molecular types of Streptococcus pneumoniae colonizing preschool-age children attending day care centers in Lisbon, Portugal: a summary of 4 years of annual surveillance. J Clin Microbiol 43:1285–1293 http://dx.doi.org/10.1128/JCM.43.3.1285-1293.2005. [PubMed]
20. Butler JC. 2004. Epidemiology of pneumococcal disease, p 148–168. In Tuomanen EI, Mitchell TJ, Morrison DA, Spratt BG (ed), The Pneumococcus. ASM Press, Washington, DC.
21. Grau I, Ardanuy C, Calatayud L, Rolo D, Domenech A, Liñares J, Pallares R. 2012. Invasive pneumococcal disease in healthy adults: increase of empyema associated with the clonal-type Sweden(1)-ST306. PLoS One 7:e42595 http://dx.doi.org/10.1371/journal.pone.0042595. [PubMed]
22. Lehmann D, Willis J, Moore HC, Giele C, Murphy D, Keil AD, Harrison C, Bayley K, Watson M, Richmond P. 2010. The changing epidemiology of invasive pneumococcal disease in aboriginal and non-aboriginal western Australians from 1997 through 2007 and emergence of nonvaccine serotypes. Clin Infect Dis 50:1477–1486 http://dx.doi.org/10.1086/652440. [PubMed]
23. Fedson DS, Musher DM, Eskola J. 1998. Pneumococcal vaccine. In Plotkin SA, Ordenstein WA (ed), Vaccines, 3rd ed. WB Saunders, Philadelphia, PA.
24. Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, Zell ER, Linder JA, Grijalva CG, Metlay JP, Finkelstein JA. 2011. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 29:3398–3412 http://dx.doi.org/10.1016/j.vaccine.2011.02.088. [PubMed]
25. Kramer MR, Rudensky B, Hadas-Halperin I, Isacsohn M, Melzer E. 1987. Pneumococcal bacteremia: no change in mortality in 30 years: analysis of 104 cases and review of the literature. Isr J Med Sci 23:174–180. [PubMed]
26. Brugger SD, Troxler LJ, Rüfenacht S, Frey PM, Morand B, Geyer R, Mühlemann K, Höck S, Thormann W, Furrer J, Christen S, Hilty M. 2016. Polysaccharide capsule composition of pneumococcal serotype 19A subtypes is unaltered among subtypes and independent of the nutritional environment. Infect Immun 84:3152–3160 http://dx.doi.org/10.1128/IAI.00474-16. [PubMed]
27. Fiore AE, Levine OS, Elliott JA, Facklam RR, Butler JC. 1999. Effectiveness of pneumococcal polysaccharide vaccine for preschool-age children with chronic disease. Emerg Infect Dis 5:828–831 http://dx.doi.org/10.3201/eid0506.990616. [PubMed]
28. Crook DW, Brueggemann AB, Sleeman KL, Peto TEA. 2004. Pneumococcal carriage, p 136–147. In Tuomanen EI, Mitchell TJ, Morrison DA, Spratt BG (ed), The Pneumococcus. ASM Press, Washington D.C.
29. Rodenburg GD, de Greeff SC, Jansen AG, de Melker HE, Schouls LM, Hak E, Spanjaard L, Sanders EA, van der Ende A. 2010. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 16:816–823 http://dx.doi.org/10.3201/eid1605.091223.
30. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O’Brien KL, Moore MR, Serotype Replacement Study Group. 2013. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med 10:e1001517 http://dx.doi.org/10.1371/journal.pmed.1001517. [PubMed]
31. Flasche S, Van Hoek AJ, Sheasby E, Waight P, Andrews N, Sheppard C, George R, Miller E. 2011. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 8:e1001017 http://dx.doi.org/10.1371/journal.pmed.1001017. [PubMed]
32. Weiser JN, Austrian R, Sreenivasan PK, Masure HR. 1994. Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization. Infect Immun 62:2582–2589. [PubMed]
33. Kim JO, Weiser JN. 1998. Association of intrastrain phase variation in quantity of capsular polysaccharide and teichoic acid with the virulence of Streptococcus pneumoniae. J Infect Dis 177:368–377 http://dx.doi.org/10.1086/514205. [PubMed]
34. Kim JO, Romero-Steiner S, Sørensen UB, Blom J, Carvalho M, Barnard S, Carlone G, Weiser JN. 1999. Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. Infect Immun 67:2327–2333. [PubMed]
35. Rosenow C, Ryan P, Weiser JN, Johnson S, Fontan P, Ortqvist A, Masure HR. 1997. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol 25:819–829 http://dx.doi.org/10.1111/j.1365-2958.1997.mmi494.x. [PubMed]
36. Fernández-Tornero C, López R, García E, Giménez-Gallego G, Romero A. 2001. A novel solenoid fold in the cell wall anchoring domain of the pneumococcal virulence factor LytA. Nat Struct Biol 8:1020–1024 http://dx.doi.org/10.1038/nsb724. [PubMed]
37. Vollmer W, Tomasz A. 2001. Identification of the teichoic acid phosphorylcholine esterase in Streptococcus pneumoniae. Mol Microbiol 39:1610–1622 http://dx.doi.org/10.1046/j.1365-2958.2001.02349.x. [PubMed]
38. Orihuela CJ, Gao G, Francis KP, Yu J, Tuomanen EI. 2004. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. J Infect Dis 190:1661–1669 http://dx.doi.org/10.1086/424596. [PubMed]
39. García P, González MP, García E, López R, García JL. 1999. LytB, a novel pneumococcal murein hydrolase essential for cell separation. Mol Microbiol 31:1275–1281 http://dx.doi.org/10.1046/j.1365-2958.1999.01238.x. [PubMed]
40. García P, Paz González M, García E, García JL, López R. 1999. The molecular characterization of the first autolytic lysozyme of Streptococcus pneumoniae reveals evolutionary mobile domains. Mol Microbiol 33:128–138 http://dx.doi.org/10.1046/j.1365-2958.1999.01455.x. [PubMed]
41. Gosink KK, Mann ER, Guglielmo C, Tuomanen EI, Masure HR. 2000. Role of novel choline binding proteins in virulence of Streptococcus pneumoniae. Infect Immun 68:5690–5695 http://dx.doi.org/10.1128/IAI.68.10.5690-5695.2000. [PubMed]
42. Weiser JN, Bae D, Fasching C, Scamurra RW, Ratner AJ, Janoff EN. 2003. Antibody-enhanced pneumococcal adherence requires IgA1 protease. Proc Natl Acad Sci U S A 100:4215–4220 http://dx.doi.org/10.1073/pnas.0637469100. [PubMed]
43. Kilian M, Mestecky J, Russell MW. 1988. Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. Microbiol Rev 52:296–303. [PubMed]
44. Sebert ME, Palmer LM, Rosenberg M, Weiser JN. 2002. Microarray-based identification of htrA, a Streptococcus pneumoniae gene that is regulated by the CiaRH two-component system and contributes to nasopharyngeal colonization. Infect Immun 70:4059–4067 http://dx.doi.org/10.1128/IAI.70.8.4059-4067.2002. [PubMed]
45. Ibrahim YM, Kerr AR, McCluskey J, Mitchell TJ. 2004. Role of HtrA in the virulence and competence of Streptococcus pneumoniae. Infect Immun 72:3584–3591 http://dx.doi.org/10.1128/IAI.72.6.3584-3591.2004. [PubMed]
46. Orihuela CJ, Radin JN, Sublett JE, Gao G, Kaushal D, Tuomanen EI. 2004. Microarray analysis of pneumococcal gene expression during invasive disease. Infect Immun 72:5582–5596 http://dx.doi.org/10.1128/IAI.72.10.5582-5596.2004. [PubMed]
47. Barocchi MA, Ries J, Zogaj X, Hemsley C, Albiger B, Kanth A, Dahlberg S, Fernebro J, Moschioni M, Masignani V, Hultenby K, Taddei AR, Beiter K, Wartha F, von Euler A, Covacci A, Holden DW, Normark S, Rappuoli R, Henriques-Normark B. 2006. A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci U S A 103:2857–2862 http://dx.doi.org/10.1073/pnas.0511017103. [PubMed]
48. LeMieux J, Hava DL, Basset A, Camilli A. 2006. RrgA and RrgB are components of a multisubunit pilus encoded by the Streptococcus pneumoniae rlrA pathogenicity islet. Infect Immun 74:2453–2456 http://dx.doi.org/10.1128/IAI.74.4.2453-2456.2006. [PubMed]
49. Sjöström K, Blomberg C, Fernebro J, Dagerhamn J, Morfeldt E, Barocchi MA, Browall S, Moschioni M, Andersson M, Henriques F, Albiger B, Rappuoli R, Normark S, Henriques-Normark B. 2007. Clonal success of piliated penicillin nonsusceptible pneumococci. Proc Natl Acad Sci U S A 104:12907–12912 http://dx.doi.org/10.1073/pnas.0705589104. [PubMed]
50. Moschioni M, Donati C, Muzzi A, Masignani V, Censini S, Hanage WP, Bishop CJ, Reis JN, Normark S, Henriques-Normark B, Covacci A, Rappuoli R, Barocchi MA. 2008. Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related. J Infect Dis 197:888–896 http://dx.doi.org/10.1086/528375. [PubMed]
51. Pancotto L, De Angelis G, Bizzarri E, Barocchi MA, Del Giudice G, Moschioni M, Ruggiero P. 2013. Expression of the Streptococcus pneumoniae pilus-1 undergoes on and off switching during colonization in mice. Sci Rep 3:2040 http://dx.doi.org/10.1038/srep02040.
52. Park IH, Kim KH, Andrade AL, Briles DE, McDaniel LS, Nahm MH. 2012. Nontypeable pneumococci can be divided into multiple cps types, including one type expressing the novel gene pspK. MBio 3:3 http://dx.doi.org/10.1128/mBio.00035-12.
53. Keller LE, Jones CV, Thornton JA, Sanders ME, Swiatlo E, Nahm MH, Park IH, McDaniel LS. 2013. PspK of Streptococcus pneumoniae increases adherence to epithelial cells and enhances nasopharyngeal colonization. Infect Immun 81:173–181 http://dx.doi.org/10.1128/IAI.00755-12.
54. Hermans PW, Adrian PV, Albert C, Estevão S, Hoogenboezem T, Luijendijk IH, Kamphausen T, Hammerschmidt S. 2006. The streptococcal lipoprotein rotamase A (SlrA) is a functional peptidyl-prolyl isomerase involved in pneumococcal colonization. J Biol Chem 281:968–976 http://dx.doi.org/10.1074/jbc.M510014200.
55. Cron LE, Bootsma HJ, Noske N, Burghout P, Hammerschmidt S, Hermans PW. 2009. Surface-associated lipoprotein PpmA of Streptococcus pneumoniae is involved in colonization in a strain-specific manner. Microbiology 155:2401–2410 http://dx.doi.org/10.1099/mic.0.026765-0.
56. Marks LR, Reddinger RM, Hakansson AP. 2012. High levels of genetic recombination during nasopharyngeal carriage and biofilm formation in Streptococcus pneumoniae. MBio 3:e00200-12 http://dx.doi.org/10.1128/mBio.00200-12.
57. Chao Y, Marks LR, Pettigrew MM, Hakansson AP. 2015. Streptococcus pneumoniae biofilm formation and dispersion during colonization and disease. Front Cell Infect Microbiol 4:194 http://dx.doi.org/10.3389/fcimb.2014.00194.
58. Marks LR, Davidson BA, Knight PR, Hakansson AP. 2013. Interkingdom signaling induces Streptococcus pneumoniae biofilm dispersion and transition from asymptomatic colonization to disease. MBio 4:e00438-13 http://dx.doi.org/10.1128/mBio.00438-13.
59. Pettigrew MM, Marks LR, Kong Y, Gent JF, Roche-Hakansson H, Hakansson AP. 2014. Dynamic changes in the Streptococcus pneumoniae transcriptome during transition from biofilm formation to invasive disease upon influenza A virus infection. Infect Immun 82:4607–4619 http://dx.doi.org/10.1128/IAI.02225-14.
60. Teele DW, Klein JO, Rosner B. 1989. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 160:83–94 http://dx.doi.org/10.1093/infdis/160.1.83.
61. Block SL. 1997. Causative pathogens, antibiotic resistance and therapeutic considerations in acute otitis media. Pediatr Infect Dis J 16:449–456 http://dx.doi.org/10.1097/00006454-199704000-00029.
62. Sierra A, Lopez P, Zapata MA, Vanegas B, Castrejon MM, Deantonio R, Hausdorff WP, Colindres RE. 2011. Non-typeable Haemophilus influenzae and Streptococcus pneumoniae as primary causes of acute otitis media in Colombian children: a prospective study. BMC Infect Dis 11:4 http://dx.doi.org/10.1186/1471-2334-11-4.
63. Rosenblut A, Napolitano C, Pereira A, Moreno C, Kolhe D, Lepetic A, Ortega-Barria E. 2017. Etiology of acute otitis media and serotype distribution of Streptococcus pneumoniae and Haemophilus influenzae in Chilean children <5 years of age. Medicine (Baltimore) 96:e5974 http://dx.doi.org/10.1097/MD.0000000000005974.
64. Pettigrew MM, Gent JF, Pyles RB, Miller AL, Nokso-Koivisto J, Chonmaitree T. 2011. Viral-bacterial interactions and risk of acute otitis media complicating upper respiratory tract infection. J Clin Microbiol 49:3750–3755 http://dx.doi.org/10.1128/JCM.01186-11.
65. Leibovitz E. 2003. Acute otitis media in pediatric medicine: current issues in epidemiology, diagnosis, and management. Paediatr Drugs 5(Suppl 1) :1–12.
66. Stahl WL, O’Toole RD. 1972. Pneumococcal neuraminidase: purification and properties. Biochim Biophys Acta 268:480–487 http://dx.doi.org/10.1016/0005-2744(72)90343-9.
67. Berry AM, Lock RA, Paton JC. 1996. Cloning and characterization of nanB, a second Streptococcus pneumoniae neuraminidase gene, and purification of the NanB enzyme from recombinant Escherichia coli. J Bacteriol 178:4854–4860 http://dx.doi.org/10.1128/jb.178.16.4854-4860.1996. [PubMed]
68. Tong HH, Blue LE, James MA, DeMaria TF. 2000. Evaluation of the virulence of a Streptococcus pneumoniae neuraminidase-deficient mutant in nasopharyngeal colonization and development of otitis media in the chinchilla model. Infect Immun 68:921–924 http://dx.doi.org/10.1128/IAI.68.2.921-924.2000. [PubMed]
69. Tong HH, Grants I, Liu X, DeMaria TF. 2002. Comparison of alteration of cell surface carbohydrates of the chinchilla tubotympanum and colonial opacity phenotype of Streptococcus pneumoniae during experimental pneumococcal otitis media with or without an antecedent influenza A virus infection. Infect Immun 70:4292–4301 http://dx.doi.org/10.1128/IAI.70.8.4292-4301.2002. [PubMed]
70. Tuomanen EI. 2000. Pathogenesis of pneumococcal inflammation: otitis media. Vaccine 19(Suppl 1) :S38–S40 http://dx.doi.org/10.1016/S0264-410X(00)00276-0.
71. Winter AJ, Comis SD, Osborne MP, Tarlow MJ, Stephen J, Andrew PW, Hill J, Mitchell TJ. 1997. A role for pneumolysin but not neuraminidase in the hearing loss and cochlear damage induced by experimental pneumococcal meningitis in guinea pigs. Infect Immun 65:4411–4418. [PubMed]
72. Comis SD, Osborne MP, Stephen J, Tarlow MJ, Hayward TL, Mitchell TJ, Andrew PW, Boulnois GJ. 1993. Cytotoxic effects on hair cells of guinea pig cochlea produced by pneumolysin, the thiol activated toxin of Streptococcus pneumoniae. Acta Otolaryngol 113:152–159 http://dx.doi.org/10.3109/00016489309135784. [PubMed]
73. Zhang JR, Mostov KE, Lamm ME, Nanno M, Shimida S, Ohwaki M, Tuomanen E. 2000. The polymeric immunoglobulin receptor translocates pneumococci across human nasopharyngeal epithelial cells. Cell 102:827–837 http://dx.doi.org/10.1016/S0092-8674(00)00071-4.
74. Kaetzel CS. 2001. Polymeric Ig receptor: defender of the fort or Trojan horse? Curr Biol 11:R35–R38 http://dx.doi.org/10.1016/S0960-9822(00)00041-5.
75. Lu L, Lamm ME, Li H, Corthesy B, Zhang JR. 2003. The human polymeric immunoglobulin receptor binds to Streptococcus pneumoniae via domains 3 and 4. J Biol Chem 278:48178–48187 http://dx.doi.org/10.1074/jbc.M306906200. [PubMed]
76. Luton F, Vergés M, Vaerman JP, Sudol M, Mostov KE. 1999. The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo. Mol Cell 4:627–632 http://dx.doi.org/10.1016/S1097-2765(00)80213-0.
77. Tong HH, McIver MA, Fisher LM, DeMaria TF. 1999. Effect of lacto-N-neotetraose, asialoganglioside-GM1 and neuraminidase on adherence of otitis media-associated serotypes of Streptococcus pneumoniae to chinchilla tracheal epithelium. Microb Pathog 26:111–119 http://dx.doi.org/10.1006/mpat.1998.0257. [PubMed]
78. Kietzman CC, Gao G, Mann B, Myers L, Tuomanen EI. 2016. Dynamic capsule restructuring by the main pneumococcal autolysin LytA in response to the epithelium. Nat Commun 7:10859 http://dx.doi.org/10.1038/ncomms10859. [PubMed]
79. Krivan HC, Roberts DD, Ginsburg V. 1988. Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAc beta 1-4Gal found in some glycolipids. Proc Natl Acad Sci U S A 85:6157–6161 http://dx.doi.org/10.1073/pnas.85.16.6157. [PubMed]
80. Howie AJ, Brown G. 1985. Effect of neuraminidase on the expression of the 3-fucosyl- N-acetyllactosamine antigen in human tissues. J Clin Pathol 38:409–416 http://dx.doi.org/10.1136/jcp.38.4.409. [PubMed]
81. Kahya HF, Andrew PW, Yesilkaya H. 2017. Deacetylation of sialic acid by esterases potentiates pneumococcal neuraminidase activity for mucin utilization, colonization and virulence. PLoS Pathog 13:e1006263 http://dx.doi.org/10.1371/journal.ppat.1006263.
82. Peltola VT, McCullers JA. 2004. Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr Infect Dis J 23(Suppl) :S87–S97 http://dx.doi.org/10.1097/01.inf.0000108197.81270.35. [PubMed]
83. McCullers JA, Bartmess KC. 2003. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 187:1000–1009 http://dx.doi.org/10.1086/368163. [PubMed]
84. Peltola VT, Murti KG, McCullers JA. 2005. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis 192:249–257 http://dx.doi.org/10.1086/430954. [PubMed]
85. Nakamura S, Davis KM, Weiser JN. 2011. Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J Clin Invest 121:3657–3665 http://dx.doi.org/10.1172/JCI57762. [PubMed]
86. McCullers JA. 2004. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 190:519–526 http://dx.doi.org/10.1086/421525. [PubMed]
87. Agarwal V, Kuchipudi A, Fulde M, Riesbeck K, Bergmann S, Blom AM. 2013. Streptococcus pneumoniae endopeptidase O (PepO) is a multifunctional plasminogen- and fibronectin-binding protein, facilitating evasion of innate immunity and invasion of host cells. J Biol Chem 288:6849–6863 http://dx.doi.org/10.1074/jbc.M112.405530. [PubMed]
88. Löfling J, Vimberg V, Battig P, Henriques-Normark B. 2011. Cellular interactions by LPxTG-anchored pneumococcal adhesins and their streptococcal homologues. Cell Microbiol 13:186–197 http://dx.doi.org/10.1111/j.1462-5822.2010.01560.x. [PubMed]
89. Jensch I, Gámez G, Rothe M, Ebert S, Fulde M, Somplatzki D, Bergmann S, Petruschka L, Rohde M, Nau R, Hammerschmidt S. 2010. PavB is a surface-exposed adhesin of Streptococcus pneumoniae contributing to nasopharyngeal colonization and airways infections. Mol Microbiol 77:22–43 http://dx.doi.org/10.1111/j.1365-2958.2010.07189.x. [PubMed]
90. Pracht D, Elm C, Gerber J, Bergmann S, Rohde M, Seiler M, Kim KS, Jenkinson HF, Nau R, Hammerschmidt S. 2005. PavA of Streptococcus pneumoniae modulates adherence, invasion, and meningeal inflammation. Infect Immun 73:2680–2689 http://dx.doi.org/10.1128/IAI.73.5.2680-2689.2005. [PubMed]
91. Tuomanen E. 2004. Attachment and invasion of the respiratory tract, p 221–237. In Tuomanen E, Mitchell T, Morrison DA, Spratt BG (ed), The Pneumococcus. ASM Press, Washington, DC.
92. Berry AM, Paton JC. 2000. Additive attenuation of virulence of Streptococcus pneumoniae by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence proteins. Infect Immun 68:133–140 http://dx.doi.org/10.1128/IAI.68.1.133-140.2000. [PubMed]
93. Feldman C, Anderson R, Cockeran R, Mitchell T, Cole P, Wilson R. 2002. The effects of pneumolysin and hydrogen peroxide, alone and in combination, on human ciliated epithelium in vitro. Respir Med 96:580–585 http://dx.doi.org/10.1053/rmed.2002.1316. [PubMed]
94. Canvin JR, Marvin AP, Sivakumaran M, Paton JC, Boulnois GJ, Andrew PW, Mitchell TJ. 1995. The role of pneumolysin and autolysin in the pathology of pneumonia and septicemia in mice infected with a type 2 pneumococcus. J Infect Dis 172:119–123 http://dx.doi.org/10.1093/infdis/172.1.119. [PubMed]
95. Tuomanen E, Rich R, Zak O. 1987. Induction of pulmonary inflammation by components of the pneumococcal cell surface. Am Rev Respir Dis 135:869–874 http://dx.doi.org/10.1164/arrd.1987.135.4.869. [PubMed]
96. Rubins JB, Charboneau D, Paton JC, Mitchell TJ, Andrew PW, Janoff EN. 1995. Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. J Clin Invest 95:142–150 http://dx.doi.org/10.1172/JCI117631. [PubMed]
97. Spellerberg B, Cundell DR, Sandros J, Pearce BJ, Idanpaan-Heikkila I, Rosenow C, Masure HR. 1996. Pyruvate oxidase, as a determinant of virulence in Streptococcus pneumoniae. Mol Microbiol 19:803–813 http://dx.doi.org/10.1046/j.1365-2958.1996.425954.x. [PubMed]
98. Berry AM, Paton JC, Hansman D. 1992. Effect of insertional inactivation of the genes encoding pneumolysin and autolysin on the virulence of Streptococcus pneumoniae type 3. Microb Pathog 12:87–93 http://dx.doi.org/10.1016/0882-4010(92)90111-Z.
99. Cundell DR, Gerard NP, Gerard C, Idanpaan-Heikkila I, Tuomanen EI. 1995. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 377:435–438 http://dx.doi.org/10.1038/377435a0. [PubMed]
100. Radin JN, Orihuela CJ, Murti G, Guglielmo C, Murray PJ, Tuomanen E. 2005. B-arrestin 1 participates in platelet-activating factor receptor-mediated endocytosis of Streptococcus pneumoniae. Infect Immu 73:7827–7835. [PubMed]
101. Weiser JN, Goldberg JB, Pan N, Wilson L, Virji M. 1998. The phosphorylcholine epitope undergoes phase variation on a 43-kilodalton protein in Pseudomonas aeruginosa and on pili of Neisseria meningitidis and Neisseria gonorrhoeae. Infect Immun 66:4263–4267. [PubMed]
102. Weiser JN, Shchepetov M, Chong ST. 1997. Decoration of lipopolysaccharide with phosphorylcholine: a phase-variable characteristic of Haemophilus influenzae. Infect Immun 65:943–950. [PubMed]
103. Loughran AJ, Tuomanen EI. 2016. Blood borne: bacterial components in mother’s blood influence fetal development. Inflamm Cell Signal 3:e1421. [PubMed]
104. Humann J, Mann B, Gao G, Moresco P, Ramahi J, Loh LN, Farr A, Hu Y, Durick-Eder K, Fillon SA, Smeyne RJ, Tuomanen EI. 2016. Bacterial peptidoglycan traverses the placenta to induce fetal neuroproliferation and aberrant postnatal behavior. Cell Host Microbe 19:388–399 http://dx.doi.org/10.1016/j.chom.2016.02.009. [PubMed]
105. Gould JM, Weiser JN. 2001. Expression of C-reactive protein in the human respiratory tract. Infect Immun 69:1747–1754 http://dx.doi.org/10.1128/IAI.69.3.1747-1754.2001. [PubMed]
106. Seachrist JL, Ferguson SS. 2003. Regulation of G protein-coupled receptor endocytosis and trafficking by Rab GTPases. Life Sci 74:225–235 http://dx.doi.org/10.1016/j.lfs.2003.09.009. [PubMed]
107. Orrskog S, Rounioja S, Spadafina T, Gallotta M, Norman M, Hentrich K, Fälker S, Ygberg-Eriksson S, Hasenberg M, Johansson B, Uotila LM, Gahmberg CG, Barocchi M, Gunzer M, Normark S, Henriques-Normark B. 2012. Pilus adhesin RrgA interacts with complement receptor 3, thereby affecting macrophage function and systemic pneumococcal disease. MBio 4:e00535-12 http://dx.doi.org/10.1128/mBio.00535-12. [PubMed]
108. Yao H, Zhang H, Lan K, Wang H, Su Y, Li D, Song Z, Cui F, Yin Y, Zhang X. 2017. Purified Streptococcus pneumoniae endopeptidase O (PepO) enhances particle uptake by macrophages in a Toll-like receptor 2- and miR-155-dependent manner. Infect Immun 85:e01012-16 http://dx.doi.org/10.1128/IAI.01012-16.
109. Loh LN, Gao G, Tuomanen EI. 2017. Dissecting bacterial cell wall entry and signaling in eukaryotic cells: an actin-dependent pathway parallels platelet-activating factor receptor-mediated endocytosis. MBio 8:e02030-16 http://dx.doi.org/10.1128/mBio.02030-16.
110. Abeyta M, Hardy GG, Yother J. 2003. Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect Immun 71:218–225 http://dx.doi.org/10.1128/IAI.71.1.218-225.2003.
111. Magee AD, Yother J. 2001. Requirement for capsule in colonization by Streptococcus pneumoniae. Infect Immun 69:3755–3761 http://dx.doi.org/10.1128/IAI.69.6.3755-3761.2001.
112. Kelly T, Dillard JP, Yother J. 1994. Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae. Infect Immun 62:1813–1819.
113. Briles DE, Crain MJ, Gray BM, Forman C, Yother J. 1992. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun 60:111–116.
114. Fine DP. 1975. Pneumococcal type-associated variability in alternate complement pathway activation. Infect Immun 12:772–778.
115. Hostetter MK. 1986. Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. J Infect Dis 153:682–693 http://dx.doi.org/10.1093/infdis/153.4.682.
116. Centers for Disease Control and Prevention. 1997. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 46:1–25.
117. Ren B, Szalai AJ, Hollingshead SK, Briles DE. 2004. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 72:114–122 http://dx.doi.org/10.1128/IAI.72.1.114-122.2004.
118. Ren B, Szalai AJ, Thomas O, Hollingshead SK, Briles DE. 2003. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun 71:75–85 http://dx.doi.org/10.1128/IAI.71.1.75-85.2003.
119. Tu AH, Fulgham RL, McCrory MA, Briles DE, Szalai AJ. 1999. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun 67:4720–4724.
120. Shaper M, Hollingshead SK, Benjamin WH Jr, Briles DE. 2004. PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun 72:5031–5040 http://dx.doi.org/10.1128/IAI.72.9.5031-5040.2004.
121. Duthy TG, Ormsby RJ, Giannakis E, Ogunniyi AD, Stroeher UH, Paton JC, Gordon DL. 2002. The human complement regulator factor H binds pneumococcal surface protein PspC via short consensus repeats 13 to 15. Infect Immun 70:5604–5611 http://dx.doi.org/10.1128/IAI.70.10.5604-5611.2002.
122. Dave S, Pangburn MK, Pruitt C, McDaniel LS. 2004. Interaction of human factor H with PspC of Streptococcus pneumoniae. Indian J Med Res 119(Suppl) :66–73.
123. Mohan S, Hertweck C, Dudda A, Hammerschmidt S, Skerka C, Hallström T, Zipfel PF. 2014. Tuf of Streptococcus pneumoniae is a surface displayed human complement regulator binding protein. Mol Immunol 62:249–264 http://dx.doi.org/10.1016/j.molimm.2014.06.029.
124. Dalia AB, Standish AJ, Weiser JN. 2010. Three surface exoglycosidases from Streptococcus pneumoniae, NanA, BgaA, and StrH, promote resistance to opsonophagocytic killing by human neutrophils. Infect Immun 78:2108–2116 http://dx.doi.org/10.1128/IAI.01125-09.
125. Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, Nakamatsu R, Pena S, Guinn BE, Furmanek SP, Persaud AK, Raghuram A, Fernandez F, Beavin L, Bosson R, Fernandez-Botran R, Cavallazzi R, Bordon J, Valdivieso C, Schulte J, Carrico RM, University of Louisville Pneumonia Study Group. 2017. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis 65:1806–1812 http://dx.doi.org/10.1093/cid/cix647.
126. Brown AO, Mann B, Gao G, Hankins JS, Humann J, Giardina J, Faverio P, Restrepo MI, Halade GV, Mortensen EM, Lindsey ML, Hanes M, Happel KI, Nelson S, Bagby GJ, Lorent JA, Cardinal P, Granados R, Esteban A, LeSaux CJ, Tuomanen EI, Orihuela CJ. 2014. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog 10:e1004383 http://dx.doi.org/10.1371/journal.ppat.1004383.
127. Musher DM, Rueda AM, Kaka AS, Mapara SM. 2007. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 45:158–165 http://dx.doi.org/10.1086/518849.
128. Reyes LF, Restrepo MI, Hinojosa CA, Soni NJ, Anzueto A, Babu BL, Gonzalez-Juarbe N, Rodriguez AH, Jimenez A, Chalmers JD, Aliberti S, Sibila O, Winter VT, Coalson JJ, Giavedoni LD, Dela Cruz CS, Waterer GW, Witzenrath M, Suttorp N, Dube PH, Orihuela CJ. 2017. Severe pneumococcal pneumonia causes acute cardiac toxicity and subsequent cardiac remodeling. Am J Respir Crit Care Med 196:609–620 http://dx.doi.org/10.1164/rccm.201701-0104OC.
129. Fillon S, Soulis K, Rajasekaran S, Benedict-Hamilton H, Radin JN, Orihuela CJ, El Kasmi KC, Murti G, Kaushal D, Gaber MW, Weber JR, Murray PJ, Tuomanen EI. 2006. Platelet-activating factor receptor and innate immunity: uptake of Gram-positive bacterial cell wall into host cells and cell-specific pathophysiology. J Immunol 177:6182–6191 http://dx.doi.org/10.4049/jimmunol.177.9.6182.
130. Alhamdi Y, Neill DR, Abrams ST, Malak HA, Yahya R, Barrett-Jolley R, Wang G, Kadioglu A, Toh CH. 2015. Circulating pneumolysin is a potent inducer of cardiac injury during pneumococcal infection. PLoS Pathog 11:e1004836 http://dx.doi.org/10.1371/journal.ppat.1004836.
131. Brissac T, Shenoy AT, Patterson LA, Orihuela CJ, Pirofski L. 2017. Cell invasion and pyruvate oxidase derived H 2O 2 are critical for Streptococcus pneumoniae mediated cardiomyocyte killing. Infect Immun 86:IAI.00569-17 http://dx.doi.org/10.1128/IAI.00569-17.
132. Durand ML, Calderwood SB, Weber DJ, Miller SI, Southwick FS, Caviness VS Jr, Swartz MN. 1993. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 328:21–28 http://dx.doi.org/10.1056/NEJM199301073280104.
133. Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, Harrison LH, Farley MM, Reingold A, Bennett NM, Craig AS, Schaffner W, Thomas A, Lewis MM, Scallan E, Schuchat A, Emerging Infections Programs Network. 2011. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 364:2016–2025 http://dx.doi.org/10.1056/NEJMoa1005384.
134. Hameed N, Tunkel AR. 2010. Treatment of drug-resistant pneumococcal meningitis. Curr Infect Dis Rep 12:274–281 http://dx.doi.org/10.1007/s11908-010-0110-7.
135. de Gans J, van de Beek D, European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. 2002. Dexamethasone in adults with bacterial meningitis. N Engl J Med 347:1549–1556 http://dx.doi.org/10.1056/NEJMoa021334.
136. Hoffmann O, Mahrhofer C, Rueter N, Freyer D, Bert B, Fink H, Weber JR. 2007. Pneumococcal cell wall-induced meningitis impairs adult hippocampal neurogenesis. Infect Immun 75:4289–4297 http://dx.doi.org/10.1128/IAI.01679-06.
137. Gerber J, Pohl K, Sander V, Bunkowski S, Nau R. 2003. Rifampin followed by ceftriaxone for experimental meningitis decreases lipoteichoic acid concentrations in cerebrospinal fluid and reduces neuronal damage in comparison to ceftriaxone alone. Antimicrob Agents Chemother 47:1313–1317 http://dx.doi.org/10.1128/AAC.47.4.1313-1317.2003.
138. Free SL, Li LM, Fish DR, Shorvon SD, Stevens JM. 1996. Bilateral hippocampal volume loss in patients with a history of encephalitis or meningitis. Epilepsia 37:400–405 http://dx.doi.org/10.1111/j.1528-1157.1996.tb00578.x.
139. Braun JS, Novak R, Herzog KH, Bodner SM, Cleveland JL, Tuomanen EI. 1999. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat Med 5:298–302 http://dx.doi.org/10.1038/6514.
140. Hanisch UK, Prinz M, Angstwurm K, Häusler KG, Kann O, Kettenmann H, Weber JR. 2001. The protein tyrosine kinase inhibitor AG126 prevents the massive microglial cytokine induction by pneumococcal cell walls. Eur J Immunol 31:2104–2115 http://dx.doi.org/10.1002/1521-4141(200107)31:7<2104::AID-IMMU2104>3.0.CO;2-3.
141. Freyer D, Manz R, Ziegenhorn A, Weih M, Angstwurm K, Döcke WD, Meisel A, Schumann RR, Schönfelder G, Dirnagl U, Weber JR. 1999. Cerebral endothelial cells release TNF-alpha after stimulation with cell walls of Streptococcus pneumoniae and regulate inducible nitric oxide synthase and ICAM-1 expression via autocrine loops. J Immunol 163:4308–4314.
142. Meli DN, Christen S, Leib SL. 2003. Matrix metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway. J Infect Dis 187:1411–1415 http://dx.doi.org/10.1086/374644.
143. Kastenbauer S, Koedel U, Pfister HW. 1999. Role of peroxynitrite as a mediator of pathophysiological alterations in experimental pneumococcal meningitis. J Infect Dis 180:1164–1170 http://dx.doi.org/10.1086/315048.
144. Weber JR, Angstwurm K, Bürger W, Einhäupl KM, Dirnagl U. 1995. Anti ICAM-1 (CD 54) monoclonal antibody reduces inflammatory changes in experimental bacterial meningitis. J Neuroimmunol 63:63–68 http://dx.doi.org/10.1016/0165-5728(95)00131-X.
145. Tuomanen EI, Saukkonen K, Sande S, Cioffe C, Wright SD. 1989. Reduction of inflammation, tissue damage, and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes. J Exp Med 170:959–969 http://dx.doi.org/10.1084/jem.170.3.959.
146. Braun JS, Sublett JE, Freyer D, Mitchell TJ, Cleveland JL, Tuomanen EI, Weber JR. 2002. Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis. J Clin Invest 109:19–27 http://dx.doi.org/10.1172/JCI12035.
147. Orihuela CJ, Fillon S, Smith-Sielicki SH, El Kasmi KC, Gao G, Soulis K, Patil A, Murray PJ, Tuomanen EI. 2006. Cell wall-mediated neuronal damage in early sepsis. Infect Immun 74:3783–3789 http://dx.doi.org/10.1128/IAI.00022-06.
148. Orihuela CJ, Mahdavi J, Thornton J, Mann B, Wooldridge KG, Abouseada N, Oldfield NJ, Self T, Ala’Aldeen DA, Tuomanen EI. 2009. Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. J Clin Invest 119:1638–1646 http://dx.doi.org/10.1172/JCI36759.
149. Ring A, Weiser JN, Tuomanen EI. 1998. Pneumococcal trafficking across the blood-brain barrier. Molecular analysis of a novel bidirectional pathway. J Clin Invest 102:347–360 http://dx.doi.org/10.1172/JCI2406.
150. Banerjee A, Van Sorge NM, Sheen TR, Uchiyama S, Mitchell TJ, Doran KS. 2010. Activation of brain endothelium by pneumococcal neuraminidase NanA promotes bacterial internalization. Cell Microbiol 12:1576–1588 http://dx.doi.org/10.1111/j.1462-5822.2010.01490.x.
151. Uchiyama S, Carlin AF, Khosravi A, Weiman S, Banerjee A, Quach D, Hightower G, Mitchell TJ, Doran KS, Nizet V. 2009. The surface-anchored NanA protein promotes pneumococcal brain endothelial cell invasion. J Exp Med 206:1845–1852 http://dx.doi.org/10.1084/jem.20090386. [PubMed]
152. Tomasz A, Saukkonen K. 1989. The nature of cell wall-derived inflammatory components of pneumococci. Pediatr Infect Dis J 8:902–903 http://dx.doi.org/10.1097/00006454-198912000-00034. [PubMed]
153. Tuomanen EI, Austrian R, Masure HR. 1995. Pathogenesis of pneumococcal infection. N Engl J Med 332:1280–1284 http://dx.doi.org/10.1056/NEJM199505113321907. [PubMed]
154. Moreillon P, Majcherczyk PA. 2003. Proinflammatory activity of cell-wall constituents from Gram-positive bacteria. Scand J Infect Dis 35:632–641 http://dx.doi.org/10.1080/00365540310016259. [PubMed]
155. Tuomanen E, Tomasz A, Hengstler B, Zak O. 1985. The relative role of bacterial cell wall and capsule in the induction of inflammation in pneumococcal meningitis. J Infect Dis 151:535–540 http://dx.doi.org/10.1093/infdis/151.3.535. [PubMed]
156. Winkelstein JA, Tomasz A. 1978. Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid. J Immunol 120:174–178. [PubMed]
157. Weber JR, Freyer D, Alexander C, Schröder NW, Reiss A, Küster C, Pfeil D, Tuomanen EI, Schumann RR. 2003. Recognition of pneumococcal peptidoglycan: an expanded, pivotal role for LPS binding protein. Immunity 19:269–279 http://dx.doi.org/10.1016/S1074-7613(03)00205-X.
158. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L, Aderem A. 2000. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc Natl Acad Sci U S A 97:13766–13771 http://dx.doi.org/10.1073/pnas.250476497. [PubMed]
159. Spellerberg B, Rosenow C, Sha W, Tuomanen EI. 1996. Pneumococcal cell wall activates NF-kappa B in human monocytes: aspects distinct from endotoxin. Microb Pathog 20:309–317 http://dx.doi.org/10.1006/mpat.1996.0029. [PubMed]
160. Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jéhanno M, Viala J, Tedin K, Taha MK, Labigne A, Zähringer U, Coyle AJ, DiStefano PS, Bertin J, Sansonetti PJ, Philpott DJ. 2003. Nod1 detects a unique muropeptide from Gram-negative bacterial peptidoglycan. Science 300:1584–1587 http://dx.doi.org/10.1126/science.1084677. [PubMed]
161. Watanabe T, Kitani A, Murray PJ, Strober W. 2004. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 5:800–808 http://dx.doi.org/10.1038/ni1092. [PubMed]
162. Davis KM, Nakamura S, Weiser JN. 2011. Nod2 sensing of lysozyme-digested peptidoglycan promotes macrophage recruitment and clearance of S. pneumoniae colonization in mice. J Clin Invest 121:3666–3676 http://dx.doi.org/10.1172/JCI57761. [PubMed]
163. Hostetter MK, Thomas ML, Rosen FS, Tack BF. 1982. Binding of C3b proceeds by a transesterification reaction at the thiolester site. Nature 298:72–75 http://dx.doi.org/10.1038/298072b0. [PubMed]
164. Hummell DS, Berninger RW, Tomasz A, Winkelstein JA. 1981. The fixation of C3b to pneumococcal cell wall polymers as a result of activation of the alternative complement pathway. J Immunol 127:1287–1289. [PubMed]
165. Weis WI, Drickamer K, Hendrickson WA. 1992. Structure of a C-type mannose-binding protein complexed with an oligosaccharide. Nature 360:127–134 http://dx.doi.org/10.1038/360127a0. [PubMed]
166. Roy S, Knox K, Segal S, Griffiths D, Moore CE, Welsh KI, Smarason A, Day NP, McPheat WL, Crook DW, Hill AV, Oxford Pneumoccocal Surveillance Group. 2002. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 359:1569–1573 http://dx.doi.org/10.1016/S0140-6736(02)08516-1.
167. Holzer TJ, Edwards KM, Gewurz H, Mold C. 1984. Binding of C-reactive protein to the pneumococcal capsule or cell wall results in differential localization of C3 and stimulation of phagocytosis. J Immunol 133:1424–1430. [PubMed]
168. Agarwal V, Sroka M, Fulde M, Bergmann S, Riesbeck K, Blom AM. 2014. Binding of Streptococcus pneumoniae endopeptidase O (PepO) to complement component C1q modulates the complement attack and promotes host cell adherence. J Biol Chem 289:15833–15844 http://dx.doi.org/10.1074/jbc.M113.530212. [PubMed]
169. Zou J, Zhou L, Hu C, Jing P, Guo X, Liu S, Lei Y, Yang S, Deng J, Zhang H. 2017. IL-8 and IP-10 expression from human bronchial epithelial cells BEAS-2B are promoted by Streptococcus pneumoniae endopeptidase O (PepO). BMC Microbiol 17:187 http://dx.doi.org/10.1186/s12866-017-1081-8. [PubMed]
170. Nau R, Eiffert H. 2002. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 15:95–110 http://dx.doi.org/10.1128/CMR.15.1.95-110.2002. [PubMed]
171. Mitchell TJ, Andrew PW, Saunders FK, Smith AN, Boulnois GJ. 1991. Complement activation and antibody binding by pneumolysin via a region of the toxin homologous to a human acute-phase protein. Mol Microbiol 5:1883–1888 http://dx.doi.org/10.1111/j.1365-2958.1991.tb00812.x. [PubMed]
172. Alcantara RB, Preheim LC, Gentry-Nielsen MJ. 2001. Pneumolysin-induced complement depletion during experimental pneumococcal bacteremia. Infect Immun 69:3569–3575 http://dx.doi.org/10.1128/IAI.69.6.3569-3575.2001. [PubMed]
173. Alcantara RB, Preheim LC, Gentry MJ. 1999. Role of pneumolysin’s complement-activating activity during pneumococcal bacteremia in cirrhotic rats. Infect Immun 67:2862–2866. [PubMed]
174. Tomasz A, Albino A, Zanati E. 1970. Multiple antibiotic resistance in a bacterium with suppressed autolytic system. Nature 227:138–140 http://dx.doi.org/10.1038/227138a0. [PubMed]
175. Jedrzejas MJ. 2001. Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev 65:187–207 http://dx.doi.org/10.1128/MMBR.65.2.187-207.2001. [PubMed]
176. Blom AM, Bergmann S, Fulde M, Riesbeck K, Agarwal V. 2014. Streptococcus pneumoniae phosphoglycerate kinase is a novel complement inhibitor affecting the membrane attack complex formation. J Biol Chem 289:32499–32511 http://dx.doi.org/10.1074/jbc.M114.610212. [PubMed]
177. Stringaris AK, Geisenhainer J, Bergmann F, Balshüsemann C, Lee U, Zysk G, Mitchell TJ, Keller BU, Kuhnt U, Gerber J, Spreer A, Bähr M, Michel U, Nau R. 2002. Neurotoxicity of pneumolysin, a major pneumococcal virulence factor, involves calcium influx and depends on activation of p38 mitogen-activated protein kinase. Neurobiol Dis 11:355–368 http://dx.doi.org/10.1006/nbdi.2002.0561. [PubMed]
178. Berry AM, Lock RA, Hansman D, Paton JC. 1989. Contribution of autolysin to virulence of Streptococcus pneumoniae. Infect Immun 57:2324–2330. [PubMed]
179. Balachandran P, Hollingshead SK, Paton JC, Briles DE. 2001. The autolytic enzyme LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin. J Bacteriol 183:3108–3116 http://dx.doi.org/10.1128/JB.183.10.3108-3116.2001. [PubMed]
180. Price KE, Greene NG, Camilli A. 2012. Export requirements of pneumolysin in Streptococcus pneumoniae. J Bacteriol 194:3651–3660 http://dx.doi.org/10.1128/JB.00114-12. [PubMed]
181. González-Juarbe N, Bradley KM, Shenoy AT, Gilley RP, Reyes LF, Hinojosa CA, Restrepo MI, Dube PH, Bergman MA, Orihuela CJ. 2017. Pore-forming toxin-mediated ion dysregulation leads to death receptor-independent necroptosis of lung epithelial cells during bacterial pneumonia. Cell Death Differ 24:917–928 http://dx.doi.org/10.1038/cdd.2017.49. [PubMed]
182. González-Juarbe N, Gilley RP, Hinojosa CA, Bradley KM, Kamei A, Gao G, Dube PH, Bergman MA, Orihuela CJ. 2015. Pore-forming toxins induce macrophage necroptosis during acute bacterial pneumonia. PLoS Pathog 11:e1005337 http://dx.doi.org/10.1371/journal.ppat.1005337. [PubMed]
183. Gilbert RJ, Jiménez JL, Chen S, Tickle IJ, Rossjohn J, Parker M, Andrew PW, Saibil HR. 1999. Two structural transitions in membrane pore formation by pneumolysin, the pore-forming toxin of Streptococcus pneumoniae. Cell 97:647–655 http://dx.doi.org/10.1016/S0092-8674(00)80775-8.
184. Steinfort C, Wilson R, Mitchell T, Feldman C, Rutman A, Todd H, Sykes D, Walker J, Saunders K, Andrew PW. 1989. Effect of Streptococcus pneumoniae on human respiratory epithelium in vitro. Infect Immun 57:2006–2013. [PubMed]
185. Rayner CF, Jackson AD, Rutman A, Dewar A, Mitchell TJ, Andrew PW, Cole PJ, Wilson R. 1995. Interaction of pneumolysin-sufficient and -deficient isogenic variants of Streptococcus pneumoniae with human respiratory mucosa. Infect Immun 63:442–447. [PubMed]
186. Paton JC, Ferrante A. 1983. Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin. Infect Immun 41:1212–1216. [PubMed]
187. Cockeran R, Theron AJ, Feldman C, Mitchel TJ, Anderson R. 2004. Pneumolysin potentiates oxidative inactivation of alpha-1-proteinase inhibitor by activated human neutrophils. Respir Med 98:865–871 http://dx.doi.org/10.1016/j.rmed.2004.02.014. [PubMed]
188. Maus UA, Srivastava M, Paton JC, Mack M, Everhart MB, Blackwell TS, Christman JW, Schlöndorff D, Seeger W, Lohmeyer J. 2004. Pneumolysin-induced lung injury is independent of leukocyte trafficking into the alveolar space. J Immunol 173:1307–1312 http://dx.doi.org/10.4049/jimmunol.173.2.1307. [PubMed]
189. Hirst RA, Rutman A, Sikand K, Andrew PW, Mitchell TJ, O’Callaghan C. 2000. Effect of pneumolysin on rat brain ciliary function: comparison of brain slices with cultured ependymal cells. Pediatr Res 47:381–384 http://dx.doi.org/10.1203/00006450-200003000-00016. [PubMed]
190. Hirst RA, Sikand KS, Rutman A, Mitchell TJ, Andrew PW, O’Callaghan C. 2000. Relative roles of pneumolysin and hydrogen peroxide from Streptococcus pneumoniae in inhibition of ependymal ciliary beat frequency. Infect Immun 68:1557–1562 http://dx.doi.org/10.1128/IAI.68.3.1557-1562.2000. [PubMed]
191. Rossjohn J, Feil SC, McKinstry WJ, Tweten RK, Parker MW. 1997. Structure of a cholesterol-binding, thiol-activated cytolysin and a model of its membrane form. Cell 89:685–692 http://dx.doi.org/10.1016/S0092-8674(00)80251-2.
192. Saunders FK, Mitchell TJ, Walker JA, Andrew PW, Boulnois GJ. 1989. Pneumolysin, the thiol-activated toxin of Streptococcus pneumoniae, does not require a thiol group for in vitro activity. Infect Immun 57:2547–2552. [PubMed]
Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.GPP3-0004-2018
2019-03-15
2019-10-15

Abstract:

Streptococcus pneumoniae (the pneumoccus) is the leading cause of otitis media, community-acquired pneumonia, and bacterial meningitis. The success of the pneumococcus stems from its ability to persist in the population as a commensal and avoid killing by immune system. This chapter first reviews the molecular mechanisms that allow the pneumococcus to colonize and spread from one anatomical site to the next. Then, it discusses the mechanisms of inflammation and cytotoxicity during emerging and classical pneumococcal infections.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

Immunohistochemical and schematic depiction of the choline biology of the pneumococcal surface. Immunogold labeling of pneumococci with TEPC-15 antibody recognizing free choline and antiautolysin antibody. These two images contrast free (A) versus CBP-bound (B) choline. Schematic view of the capsule (blue), cell wall (green), and membrane (red). The teichoic and lipoteichoic acids are indicated as dark blue lines bearing choline (circles). A proportion of these are capped by choline-binding proteins. Courtesy of K.G. Murti, St. Jude Electron Microscopy Core Facility.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0004-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

Schematic depiction of the spread and progression of infection. Carriage of the pneumococcus occurs in the nasopharynx and is usually asymptomatic in healthy individuals. The bacteria are spread by aerosol from the nasopharynx of carriers. The pneumococcus can spread from the nasopharynx to a number of different tissues. In children the bacteria usually causes otitis media. Invasive diseases generally start in the lungs and spread to the blood, with the most serious complication being meningitis. The switch from asymptomatic colonization to invasive disease in healthy individuals usually occurs when there is a disruption in the innate immune defenses. (This figure contains some artwork produced by Servier Medical Art [http://smart.servier.com/] under Creative Commons license 3.0).

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0004-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3
FIGURE 3

Schematic representation of the pneumococcus hijacking the pIgR/IgA system to cross the mucosal epithelia into the blood. Mucosal epithelial cells transport IgA (black) from the basolateral to the apical surface using the receptor pIgR (green). This receptor is then endocytosed and recycled back to the basolateral surface to transport more IgA. To protect itself from IgA, the pneumococcus produces the protease sIgA1 (yellow), which cleaves the host IgA into Fab fragments. The choline-binding protein, CbpA (red), binds to the empty pIgR and shuttles the pneumococcus from the apical side to the basolateral side of the epithelial cells. (This figure contains some artwork produced by Servier Medical Art [http://smart.servier.com/] under Creative Commons license 3.0).

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0004-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 4
FIGURE 4

Structure of the pneumococcal cell wall and its relationship to inflammation. Penicillin induces cell wall degradation by the autolysin releasing cell wall fragments such as lipoteichoic acid, glycan polymers with and without teichoic acid, and small stem peptides. All teichoicated species contain ChoP, a key component increasing inflammatory activity. All of these components interact with a variety of human cells, which in turn produce inflammatory mediators. Particularly important in this response is the platelet activating factor (PAFr). These mediators combine to produce the symptomatology of pneumococcal infection, including changes in blood flow, fluid balance in the tissue, and leukocytosis. Glc, glucose; TDH, trideoxyhexose; NAcGaln, -acetylgalctosamine; Galn, galactosamine; -Ala, -alanine; -Glu, -glucose; -Lys, -lysine; TNF, tumor necrosis factor; NO, nitric oxide; PGE2, prostaglandin E2; IC pressure, intracranial pressure; MIPS, macrophage inflammatory protein.

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0004-2018
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 5
FIGURE 5

Domain structure of pneumolysin. Pneumolysin has three functionally separate domains: one activating complement, one causing hemolysis, and the other binding to cholesterol. Site-specific mutations alter these properties individually ( 191 , 192 ).

Source: microbiolspec March 2019 vol. 7 no. 2 doi:10.1128/microbiolspec.GPP3-0004-2018
Permissions and Reprints Request Permissions
Download as Powerpoint

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error